Search Results - "Krais, John J"

RNF168-mediated localization of BARD1 recruits the BRCA1-PALB2 complex to DNA damage by Krais, John J., Wang, Yifan, Patel, Pooja, Basu, Jayati, Bernhardy, Andrea J., Johnson, Neil

“…DNA damage prompts a diverse range of alterations to the chromatin landscape. The RNF168 E3 ubiquitin ligase catalyzes the mono-ubiquitination of histone H2A…”
Get full text

Structural basis for a Polθ helicase small-molecule inhibitor revealed by cryo-EM by Ito, Fumiaki, Li, Ziyuan, Minakhin, Leonid, Chandramouly, Gurushankar, Tyagi, Mrityunjay, Betsch, Robert, Krais, John J., Taberi, Bernadette, Vekariya, Umeshkumar, Calbert, Marissa, Skorski, Tomasz, Johnson, Neil, Chen, Xiaojiang S., Pomerantz, Richard T.

“…DNA polymerase theta (Polθ) is a DNA helicase-polymerase protein that facilitates DNA repair and is synthetic lethal with homology-directed repair (HDR)…”
Get full text

BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance by Wang, Yifan, Bernhardy, Andrea J., Nacson, Joseph, Krais, John J., Tan, Yin-Fei, Nicolas, Emmanuelle, Radke, Marc R., Handorf, Elizabeth, Llop-Guevara, Alba, Balmaña, Judith, Swisher, Elizabeth M., Serra, Violeta, Peri, Suraj, Johnson, Neil

“…BRCA1 mutant carcinomas are sensitive to PARP inhibitor (PARPi) therapy; however, resistance arises. BRCA1 BRCT domain mutant proteins do not fold correctly…”
Get full text

Discovery of a small-molecule inhibitor that traps Polθ on DNA and synergizes with PARP inhibitors by Fried, William, Tyagi, Mrityunjay, Minakhin, Leonid, Chandramouly, Gurushankar, Tredinnick, Taylor, Ramanjulu, Mercy, Auerbacher, William, Calbert, Marissa, Rusanov, Timur, Hoang, Trung, Borisonnik, Nikita, Betsch, Robert, Krais, John J., Wang, Yifan, Vekariya, Umeshkumar M., Gordon, John, Morton, George, Kent, Tatiana, Skorski, Tomasz, Johnson, Neil, Childers, Wayne, Chen, Xiaojiang S., Pomerantz, Richard T.

“…The DNA damage response (DDR) protein DNA Polymerase θ (Polθ) is synthetic lethal with homologous recombination (HR) factors and is therefore a promising drug…”
Get full text

BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance by Nacson, Joseph, Krais, John J., Bernhardy, Andrea J., Clausen, Emma, Feng, Wanjuan, Wang, Yifan, Nicolas, Emmanuelle, Cai, Kathy Q., Tricarico, Rossella, Hua, Xiang, DiMarcantonio, Daniela, Martinez, Esteban, Zong, Dali, Handorf, Elizabeth A., Bellacosa, Alfonso, Testa, Joseph R., Nussenzweig, Andre, Gupta, Gaorav P., Sykes, Stephen M., Johnson, Neil

“…BRCA1 functions in homologous recombination (HR) both up- and downstream of DNA end resection. However, in cells with 53BP1 gene knockout (KO), BRCA1 is…”
Get full text

Genetic separation of Brca1 functions reveal mutation-dependent Polθ vulnerabilities by Krais, John J., Glass, David J., Chudoba, Ilse, Wang, Yifan, Feng, Wanjuan, Simpson, Dennis, Patel, Pooja, Liu, Zemin, Neumann-Domer, Ryan, Betsch, Robert G., Bernhardy, Andrea J., Bradbury, Alice M., Conger, Jason, Yueh, Wei-Ting, Nacson, Joseph, Pomerantz, Richard T., Gupta, Gaorav P., Testa, Joseph R., Johnson, Neil

“…Homologous recombination (HR)-deficiency induces a dependency on DNA polymerase theta (Polθ/ Polq )-mediated end joining, and Polθ inhibitors (Polθi) are in…”
Get full text

Purine nucleoside phosphorylase targeted by annexin v to breast cancer vasculature for enzyme prodrug therapy by Krais, John J, De Crescenzo, Olivier, Harrison, Roger G

“…The targeting of therapeutics is a promising approach for the development of new cancer treatments that seek to reduce the devastating side effects caused by…”
Get full text

Antitumor Synergism and Enhanced Survival with a Tumor Vasculature-Targeted Enzyme Prodrug System, Rapamycin, and Cyclophosphamide by Krais, John J, Virani, Needa, McKernan, Patrick H, Nguyen, Quang, Fung, Kar-Ming, Sikavitsas, Vassilios I, Kurkjian, Carla, Harrison, Roger G

“…Mutant cystathionine gamma-lyase was targeted to phosphatidylserine exposed on tumor vasculature through fusion with Annexin A1 or Annexin A5. Cystathionine…”
Get full text

BRCA1 Mutations in Cancer: Coordinating Deficiencies in Homologous Recombination with Tumorigenesis by Krais, John J, Johnson, Neil

“…Cancers that arise from germline mutations are deficient for homologous recombination (HR) DNA repair and are sensitive to DNA-damaging agents such as platinum…”
Get full text

Ectopic RNF168 expression promotes break-induced replication-like DNA synthesis at stalled replication forks by Krais, John J, Johnson, Neil

“…The RNF168 E3 ubiquitin ligase is activated in response to double stranded DNA breaks (DSBs) where it mono-ubiquitinates γH2AX (ub-H2AX). RNF168 protein…”
Get full text

Replication Gaps Underlie BRCA Deficiency and Therapy Response by Panzarino, Nicholas J, Krais, John J, Cong, Ke, Peng, Min, Mosqueda, Michelle, Nayak, Sumeet U, Bond, Samuel M, Calvo, Jennifer A, Doshi, Mihir B, Bere, Matt, Ou, Jianhong, Deng, Bin, Zhu, Lihua J, Johnson, Neil, Cantor, Sharon B

“…Defects in DNA repair and the protection of stalled DNA replication forks are thought to underlie the chemosensitivity of tumors deficient in the hereditary…”
Get full text

The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin by Wang, Yifan, Bernhardy, Andrea J, Cruz, Cristina, Krais, John J, Nacson, Joseph, Nicolas, Emmanuelle, Peri, Suraj, van der Gulden, Hanneke, van der Heijden, Ingrid, O'Brien, Shane W, Zhang, Yong, Harrell, Maribel I, Johnson, Shawn F, Candido Dos Reis, Francisco J, Pharoah, Paul D P, Karlan, Beth, Gourley, Charlie, Lambrechts, Diether, Chenevix-Trench, Georgia, Olsson, Håkan, Benitez, Javier J, Greene, Mark H, Gore, Martin, Nussbaum, Robert, Sadetzki, Siegal, Gayther, Simon A, Kjaer, Susanne K, D'Andrea, Alan D, Shapiro, Geoffrey I, Wiest, David L, Connolly, Denise C, Daly, Mary B, Swisher, Elizabeth M, Bouwman, Peter, Jonkers, Jos, Balmaña, Judith, Serra, Violeta, Johnson, Neil

“…Breast and ovarian cancer patients harboring BRCA1/2 germline mutations have clinically benefitted from therapy with PARP inhibitor (PARPi) or platinum…”
Get full text

ATF3 coordinates serine and nucleotide metabolism to drive cell cycle progression in acute myeloid leukemia by Di Marcantonio, Daniela, Martinez, Esteban, Kanefsky, Joice S., Huhn, Jacklyn M., Gabbasov, Rashid, Gupta, Anushk, Krais, John J., Peri, Suraj, Tan, YinFei, Skorski, Tomasz, Dorrance, Adrienne, Garzon, Ramiro, Goldman, Aaron R., Tang, Hsin-Yao, Johnson, Neil, Sykes, Stephen M.

“…Metabolic reprogramming is a common feature of many human cancers, including acute myeloid leukemia (AML). However, the upstream regulators that promote AML…”
Get full text

RNF168-Mediated Ubiquitin Signaling Inhibits the Viability of BRCA1 -Null Cancers by Krais, John J, Wang, Yifan, Bernhardy, Andrea J, Clausen, Emma, Miller, Jessica A, Cai, Kathy Q, Scott, Clare L, Johnson, Neil

“…gene mutations impair homologous recombination (HR) DNA repair, resulting in cellular senescence and embryonic lethality in mice. Therefore, BRCA1-deficient…”
Get full text

RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance by Wang, Yifan, Krais, John J, Bernhardy, Andrea J, Nicolas, Emmanuelle, Cai, Kathy Q, Harrell, Maria I, Kim, Hyoung H, George, Erin, Swisher, Elizabeth M, Simpkins, Fiona, Johnson, Neil

“…Patients with cancers that harbor breast cancer 1 (BRCA1) mutations initially respond well to platinum and poly(ADP-ribose) polymerase inhibitor (PARPi)…”
Get full text

Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition by Gabbasov, Rashid, Benrubi, I. Daniel, O'Brien, Shane W., Krais, John J., Johnson, Neil, Litwin, Samuel, Connolly, Denise C.

“…Pharmacological inhibition of PARP is a promising approach in treating high grade serous ovarian carcinoma (HGSOC). PARP inhibitors (PARPi) are most active in…”
Get full text

4'-Ethynyl-2'-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress by Calbert, Marissa L, Chandramouly, Gurushankar, Adams, Clare M, Saez-Ayala, Magali, Kent, Tatiana, Tyagi, Mrityunjay, Ayyadevara, V S S Abhinav, Wang, Yifan, Krais, John J, Gordon, John, Atkins, Jessica, Toma, Monika M, Betzi, Stéphane, Boghossian, Andrew S, Rees, Matthew G, Ronan, Melissa M, Roth, Jennifer A, Goldman, Aaron R, Gorman, Nicole, Mitra, Ramkrishna, Childers, Wayne E, Graña, Xavier, Skorski, Tomasz, Johnson, Neil, Hurtz, Christian, Morelli, Xavier, Eischen, Christine M, Pomerantz, Richard T

“…Anticancer nucleosides are effective against solid tumors and hematologic malignancies, but typically are prone to nucleoside metabolism resistance mechanisms…”
Get more information

Targeting single-walled carbon nanotubes for the treatment of breast cancer using photothermal therapy by Neves, Luís F F, Krais, John J, Van Rite, Brent D, Ramesh, Rajagopal, Resasco, Daniel E, Harrison, Roger G

“…This paper focuses on the targeting of single-walled carbon nanotubes (SWNTs) for the treatment of breast cancer with minimal side effects using photothermal…”
Get more information

BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance by Nacson, Joseph, Krais, John J, Bernhardy, Andrea J, Clausen, Emma, Feng, Wanjuan, Wang, Yifan, Nicolas, Emmanuelle, Cai, Kathy Q, Tricarico, Rossella, Hua, Xiang, DiMarcantonio, Daniela, Martinez, Esteban, Zong, Dali, Handorf, Elizabeth A, Bellacosa, Alfonso, Testa, Joseph R, Nussenzweig, Andre, Gupta, Gaorav P, Sykes, Stephen M, Johnson, Neil

Get full text

Antitumor Activity of an Enzyme Prodrug Therapy Targeted to the Breast Tumor Vasculature by Van Rite, Brent D., Krais, John J., Cherry, Mohamad, Sikavitsas, Vassilios I., Kurkjian, Carla, Harrison, Roger G.

“…The L-methioninase-annexin V/selenomethionine enzyme prodrug system, designed to target the tumor vasculature and release the methylselenol anticancer drug in…”
Get full text